EQRx Revenue and Competitors

Boston, MA USA

Location

$1.9B

Total Funding

Estimated Revenue & Valuation

  • EQRx's estimated annual revenue is currently $31.3M per year.(i)
  • EQRx's estimated revenue per employee is $150,500
  • EQRx's total funding is $1.9B.
  • EQRx's current valuation is $1.2B.

Employee Data

  • EQRx has 208 Employees.(i)
  • EQRx grew their employee count by -34% last year.

EQRx's People

NameTitleEmail/Phone
1
Sr. VP, Clinical OperationsReveal Email/Phone
2
Chief Regulatory AffairsReveal Email/Phone
3
Chief Physician ExecutiveReveal Email/Phone
4
CEOReveal Email/Phone
5
Chief Rx CreationReveal Email/Phone
6
Chief Technical Operations and QualityReveal Email/Phone
7
Chief Executive PhysicianReveal Email/Phone
8
VP, Alliance ManagementReveal Email/Phone
9
SVP, BiologicsReveal Email/Phone
10
VP, Accounting & Finance OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$31.3M208-34%$1.9B$1.2B
Add Company

What Is EQRx?

EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.

keywords:N/A

$1.9B

Total Funding

208

Number of Employees

$31.3M

Revenue (est)

-34%

Employee Growth %

$1.2B

Valuation

N/A

Accelerator

EQRx News

2022-04-17 - EQRx (NASDAQ:EQRX) Now Covered by Analysts at Cowen

Jefferies Financial Group initiated coverage on EQRx in a research note on Friday, March 18th. They set a “buy” rating and a $5.60 price target...

2022-04-13 - Brokerages Anticipate EQRx, Inc. (NASDAQ:EQRX) to ...

Zero analysts have provided estimates for EQRx's earnings. The business is expected to issue its next quarterly earnings results on Monday,...

2022-03-30 - EQRx Price Disruptor Business Model Faces The Costly ...

EQRx's aim is for the purchasing network to support its first two drugs and others that come along. The company has a portfolio of eight other...

2021-11-16 - EQRx Launches “Remaking Medicine: On The Record” Investor Video Series

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today launched a multi-part corporate video series entitled “Remaking Medicine: On The Record.” The series is moderated by Jami Rubin, EQRx’s chief fin ...

2021-08-10 - UP­DAT­ED: Vir­tu­al­ly un­known mR­NA up­start rides SPAC to Nas­daq with a $1.5B val­u­a­tion as RA-backed neu­ro play­er prices IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here. Just a few days af­ter EQRx an­nounced its in­tent to merge with Eli Cas­din’s third blank check com­pa­ny, an­oth­er SPAC deal is wrapped up and ready for Nas­daq. RNA ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33.3M209-3%N/A
#2
$48.3M209-5%N/A
#3
$32.6M21220%N/A
#4
$24M214-1%N/A
#5
$6.2M217-1%$395.5M